Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncothyreon Has Big Plans For Alpine Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

One Seattle biotech took over another Seattle biotech in hopes of making a stronger oncology player that has the capabilities to develop its own drugs. It also hopes the acquisition will give it more business development opportunities.

You may also be interested in...



Deal Watch: Allergan Makes Another Defensive Play Against Valeant Takeover

In a pair of diabetes-related transaction, Sanofi pays $175 million upfront to MannKind for worldwide license to inhaled insulin Afrezza, while Janssen options Phase I stem cell program from ViaCyte. Novartis gets purchase option for stem-cell biotech Gamida Cell and MorphoSys in-licenses a preclinical prostate cancer antibody candidate from Emergent BioSolutions.

Celldex Differentiated Immuno-Oncology Asset Ripe For Combos

Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.

Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates

While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS077545

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel